OX2 Therapeutics has reached RP2D in its ongoing clinical trial evaluating ARL200 + GBM6-AD Vaccine in pediatric patients with newly diagnosed Diffuse Midline Glioma and recurrent High-Grade Glioma.
OX2 Therapeutics has begun a Phase I clinical trial for a first-of-its-kind immunotherapy targeting aggressive brain tumors, aiming to boost the immune system and improve outcomes for patients.
OX2 Therapeutics has received clearance from the U.S. Food and Drug Administration to launch a phase 1 clinical trial with its new combination therapy for treatment of recurrent high grade brain tumors for which no curative therapy is available.